The US Food and Drug Administration (FDA) has awarded regulatory clearance for the Arcuro Medical’s (Arcuro) SuperBall meniscus repair system.

A Trendlines Group portfolio company, Arcuro Medical has developed the all-suture meniscus repair system to maintain knee functionality.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Recently, the company also secured patent for this system in the US.

“Arcuro expects that this easy-to-use system will enable the surgeons to repair the meniscus instead of removing it.”

Arcuro CEO Lee Ranon said: “We are very excited to have achieved FDA clearance in addition to the news of receiving our US patent.

“These two important milestones will enable the company to begin its clinical evaluation phase straight away.”

Meniscus tears are common among various population groups but are predominant among sportspersons, ageing people or patients with cartilage problems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The standard treatment avoids the removal of the meniscus and involves arthroscopic repair techniques, which may result in rigid implants and inconvenient delivery systems.

It may also lead to long-term damage to the meniscus, poor repair and higher chances of intraoperative failure.

Stated to be secure and effective, the SuperBall meniscus repair system underwent a series of pre-clinical studies in the US and Israel.

Arcuro expects that this easy-to-use system will enable the surgeons to repair the meniscus instead of removing it.

The Trendlines Group chairman and CEO Steve Rhodes said: “We are very proud of the progress that the Arcuro team has made towards bringing their SuperBall meniscus repair system to market.

“We look forward to following their progress in improving patient outcomes and reducing surgeries in a market seeking a solution to this common and painful problem.”

Arcuro has already submitted a patent application at national phase in China, Israel and Europe.